Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Vaccination Against Herpes Zoster

Research output: Contribution to journalReviewResearchpeer-review

  1. Orbital cysticercosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Palytoksinforgiftning relateret til saltvandsakvarie

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Presence of SARS-CoV-2 in semen and the impact of COVID-19 on the male reproductive system

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Flying fattens and swimming slims - the secret of the mermaid

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Behandling af mandlig infertilitet

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

During their lifetime, 25% of Danes will experience an episode of herpes zoster (HZ). In 15-20% of these 25% HZ will be complicated by postherpetic neuralgia (PHN). The European Medicines Agency has approved two vaccines against HZ, a live attenuated vaccine (ZLV) and a recombinant adjuvanted vaccine (RZV). The efficacy of ZLV against HZ is moderate (51%), age-dependent and declines in 5-8 years. RZV has shown greater-than 90% protection against HZ and PHN across age groups for ≥ 9 years as summarised in this review. Vaccination of everybody > 50 years of age and immunocompromised patients > 18 years of age against HZ with RZV is recommend in several countries and should also be considered in Denmark.

Translated title of the contributionVaccination against herpes zoster
Original languageDanish
JournalUgeskrift for Laeger
Volume183
Issue number47
ISSN0041-5782
Publication statusPublished - 22 Nov 2021

ID: 69565814